Noxopharm White Paper

11 Disclaimer: Veyonda is currently not approved in Australia or any other country Veyonda® – LuPIN program LuPIN: Lutetium-PSMA In Combination with NOX66 (Veyonda) LuPIN aims: • To enhance in men with metastatic castrate-resistant prostate cancer (mCRPC), the anti-cancer response to the radioligand, 177 Lutetium-PSMA-617, resulting in longer patient survival. • To enable patients to complete their full course of radioligand therapy. LuPIN rationale: • Response to 177 Lutetium-PSMA-617 is limited by rates of expression by cancer cells of PSMA (prostate surface membrane antigen) protein which in many men is limited, thereby leading to delivery of potentially sub-lethal doses of radiation. • Primary benefit of idronoxil in this combination setting believed to be a direct radio-enhancing effect, with mitotic arrest exposing DNA to maximum radiation-induced damage, and inhibition of DNA repair, reducing the cell’s ability to repair that damage, and thereby converting a sub- lethal dose of radiation into a more lethal dose. LuPIN Program objectives: To show that: • A combination of Veyonda + 177 Lutetium-PSMA-617 is well tolerated. • A combination of Veyonda + 177 Lutetium-PSMA-617 provides a meaningful increase in median overall survival compared to standard of care or to 177 Lutetium-PSMA-617 treatment alone. • The combination treatment has the capacity to become standard of care in mCRPC as 1st, 2nd or 3rd line therapy.